Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema in Eyes with Branch Retinal Vein Occlusion with vs Without Glaucoma – Does Glaucoma Affect Visual Outcome in Eyes with BRVO-ME After antiVEGF Injections?

Figures & data

Table 1 Baseline Characteristics of the Patients

	G [-]	G [+]	P-value
Age (years)	69.8±11.1	72.0±10.9	0.29
N (F: M)	28 (11:17)	27 (9:18)	0.64
CRT (µm)	514.2±117.3	533.4±171.4	0.5
BCVA (logMAR)	0.42±0.32	0.57±0.33	0.12
Agent (A: B: R)	5:1:24	3:10:14	0.02*
IOP (mmHg)	12.7	15.8	0.18

Notes: Data are presented as the means ± standard deviations. Mann–Whitney U-test was used to determine the significance of the differences between the groups. Chi-square test was used to determine the significance of differences among the groups. *P < 0.05.

Abbreviations: G [-], macular edema associated with branch retinal vein occlusion without glaucoma; G [+], macular edema associated with branch retinal vein occlusion with glaucoma; BCVA, best corrected visual acuity; CRT, central retinal thickness; IOP, intraocular pressure; A, aflibercept; B, bevacizumab; R, ranibizumab.

Figure 1 The best-corrected visual acuity (BCVA) and central sub-retinal thickness (CRT) at 3 months after a single anti-VEGF injection for eyes without glaucoma (G [-]) and with glaucoma (G [+]). BCVA and CRT significantly improved in both groups during the experimental period. Baseline BCVA did not differ significantly between the two groups (A and B). The two groups showed no significant difference at 1 month after treatment, but the BCVA was significantly worse in the G [+] group than in the G [-] group at 3 months after treatment (P = 0.02).

Notes: Line: BRVO without glaucoma, broken line: BRVO with glaucoma.*P < 0.05, **P < 0.01.

Abbreviations: G [-], macular edema associated with BRVO without glaucoma; G [+], macular edema associated with BRVO with glaucoma; BCVA, best-corrected visual acuity; BRVO, branch retinal vein occlusion; CRT, central retinal thickness; VEGF, vascular endothelial growth factor; ns, not significant.